Navigation Links
First targeted and programmable nanomedicine to show clinical antitumor effects published
Date:4/4/2012

stitute, Weill Cornell Medical College, the Translational Genomics Research Institute (TGen), Karmanos Cancer Institute and Wayne State University.

"We are very excited about the results of our preclinical development, and successful clinical translation of BIND-014. The initial Phase 1 clinical efficacy and safety in advanced and metastatic cancers demonstrate promise for BIND-014 and provide strong validation for our Accurin platform to develop targeted therapeutics that accumulate at the site of disease to maximize therapeutic effect," said Jeff Hrkach, Ph.D., Senior Vice President, Technology Research and Development of BIND Biosciences. "BIND-014 represents the lead Accurin product to enter the clinic from our pipeline and is an ideal example of the power of our proprietary platform to develop targeted therapeutics."

About BIND-014

BIND-014 is a programmable nanomedicine that combines a targeting ligand and a therapeutic nanoparticle. BIND-014 contains docetaxel, a proven cancer drug which is approved in major cancer indications including breast, prostate and lung, encapsulated in FDA-approved biocompatible and biodegradable polymers. BIND-014 is targeted to prostate specific membrane antigen (PSMA), a cell surface antigen abundantly expressed on the surface of cancer cells and on new blood vessels that feed a wide array of solid tumors. In preclinical cancer models, BIND-014 was shown to deliver up to ten-fold more docetaxel to tumors than an equivalent dose of conventional docetaxel. The increased accumulation of docetaxel at the site of disease translated to marked improvements in antitumor activity and tolerability. BIND-014 is currently in Phase 1 human clinical testing in patients with advanced or metastatic solid tumor cancers (NCT01300533). The early development of BIND-014 was funded in part by the National Cancer Institute and the U.S. National Institutes of Standards and Technology (NIST) under its Advanced Technology Program
'/>"/>

Contact: Kathryn Morris
kathryn@theyatesnetwork.com
914-204-6412
The Yates Network
Source:Eurekalert

Page: 1 2 3 4

Related biology technology :

1. MiMedx Exceeds Revenue Goal for First Quarter of 2012
2. FirstMark Exhibiting at the American College of Cardiology 61st Annual Scientific Sessions & Expo
3. Expanded Findings for FirstMarks Completed Clinical Study for Predicting Near-Term (2-3 Years) MI
4. Jennerex Announces First Patient Treated in Phase 1/2 Clinical Trial of JX-594 in Combination with Irinotecan in Patients with Metastatic Colorectal Cancer
5. Researchers capture first-ever images of atoms moving in a molecule
6. Be One of the First to Experience Medtrack One View at the AUTM 2012 Annual Meeting
7. First Statewide Biotech Meeting Focuses on Patient Access, Innovation
8. Inaugural Meeting of the FirstMark Scientific Board of Advisors
9. AtheroNova Achieves Milestone in Initiating First Shipment of AHRO-001
10. China Cord Blood Corporation Reports Financial Results for the Third Quarter and First Nine Months of Fiscal 2012
11. Penn researchers build first physical metatronic circuit
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/26/2015)... ... 26, 2015 , ... Maine Standards Company, LLC is pleased ... kit. The VALIDATE® ANEMIA kit contains Ferritin, Folate, and Vitamin B12 in a ... recommended “equal delta” method for linearity testing and is liquid, ready-to-use. Simply add ...
(Date:7/24/2015)... 2015 Ryan & Maniskas, LLP that ... District Court for the Northern District of California ... purchased the common stock of Avalanche Biotechnologies, Inc. ("Avalanche" or ... and June 15, 2015, inclusive (the "Class Period"). ... the Court for appointment as a lead plaintiff of the ...
(Date:7/24/2015)... , July 24, 2015 ... equities: PDL BioPharma Inc. (NASDAQ: PDLI ), Arena ... STEM ), Northwest Biotherapeutics Inc. (NASDAQ: NWBO ... Free research report on PDL BioPharma can be accessed ... the NASDAQ Composite ended at 5,146.41, down 0.49%, the ...
(Date:7/24/2015)... , July 24, 2015 Orexigen Therapeutics, ... financial results for the second quarter 2015 on Thursday, ... Orexigen will provide a business update and discuss the ... at 8:00 a.m. Eastern Time (5:00 a.m. Pacific Time). ... phone by calling (800) 447-0521 (domestic) or (847) 413-3238 ...
Breaking Biology Technology:Maine Standards Company, LLC Announces Release of VALIDATE® ANEMIA Calibration Verification / Linearity Test Kit 2Ryan & Maniskas, LLP Announces Class Action Lawsuit Against Avalanche Biotechnologies, Inc. 2Ryan & Maniskas, LLP Announces Class Action Lawsuit Against Avalanche Biotechnologies, Inc. 3Biotechnology Stocks in Motion -- PDL BioPharma, Arena Pharma, StemCells, Northwest Biotherapeutics, and Acorda Therapeutics 2Biotechnology Stocks in Motion -- PDL BioPharma, Arena Pharma, StemCells, Northwest Biotherapeutics, and Acorda Therapeutics 3Biotechnology Stocks in Motion -- PDL BioPharma, Arena Pharma, StemCells, Northwest Biotherapeutics, and Acorda Therapeutics 4Biotechnology Stocks in Motion -- PDL BioPharma, Arena Pharma, StemCells, Northwest Biotherapeutics, and Acorda Therapeutics 5
... financial numbers for the end of fiscal 2005 on Thursday, ... ,Revenues were $8.3 million, an 89 percent increase over the ... to multiple unit sales, repeat purchases, new product offerings and ... however, and the company posted a loss of $4.2 million, ...
... Wisconsin in the next ten years, according to a proposal ... reach the Senate for a vote this month. State Senator ... in Wisconsin that would be regulated similarly to airports. , ... to regulate private space travel in the area, receive any ...
... investors in early-stage companies has shown results in its first ... so far applied for $1.8 million of the $3 million ... figures show. But of the $3.5 million in tax credits ... ,"We knew there would be a lag on the venture ...
Cached Biology Technology:Space port could open in Sheboygan in next 10 years 2Space port could open in Sheboygan in next 10 years 3Act 255 heats up angel investment in 2005, though VC involvement lags 2Act 255 heats up angel investment in 2005, though VC involvement lags 3
(Date:7/13/2015)... OXFORD, Conn. , Jul. 13, 2015 /PRNewswire/ ... the "Company"), a biometric authentication company focused on ... it has filed provisional patent 62/188684 for ... NXT-ID achieves another new convenient and secure method ... expands new, innovative payment methods, introduced with its ...
(Date:7/8/2015)... 8, 2015 Summary Pancreatic cancer is ... most fatal, with a mortality rate of 10.9 deaths ... pancreatic cancer patients has highlighted a significant need for ... being met by the current market. A highly ... with varying molecule types and mechanisms of action, which ...
(Date:7/7/2015)... VIEW, Calif. , July 7, 2015 /PRNewswire/ ... biometrics market, Frost & Sullivan recognizes Credence ID, ... Sullivan Entrepreneurial Company of the Year Award. ... suite to aid in its mission of offering ... under-recognized populations globally. As Credence ID was formed ...
Breaking Biology News(10 mins):NXT-ID Patents Behavior-Directed Payments 2NXT-ID Patents Behavior-Directed Payments 3NXT-ID Patents Behavior-Directed Payments 4Frontier Pharma: Pancreatic Cancer - Identifying and Commercializing First-in-Class Innovation 2Frontier Pharma: Pancreatic Cancer - Identifying and Commercializing First-in-Class Innovation 3Frost & Sullivan Acknowledges the Distinctive Customer-focused Attributes of Credence ID's Mobile Biometric Product Suite 2Frost & Sullivan Acknowledges the Distinctive Customer-focused Attributes of Credence ID's Mobile Biometric Product Suite 3Frost & Sullivan Acknowledges the Distinctive Customer-focused Attributes of Credence ID's Mobile Biometric Product Suite 4Frost & Sullivan Acknowledges the Distinctive Customer-focused Attributes of Credence ID's Mobile Biometric Product Suite 5
... Providing food security, one of the greatest challenges ... the developing world, where crop destruction by drought, disease ... risk of hunger. Scientists at the University of ... on cowpea, a protein-rich legume crop of immense importance ...
... NJ Uncover the neural communication links involved in ... it may become possible to reverse the breakdown of ... multiple sclerosis, spinal cord injuries, diabetes and cancers of ... the New Jersey Commission on Spinal Cord Injury and ...
... 14 satellites currently in orbit and the National Aeronautics ... been able to observe the Earths environment to help ... The use of remote sensing technology aids specialists ... common and deadly infectious diseases today such as Ebola, ...
Cached Biology News:UCR researchers awarded nearly $1.7M to develop improved cowpea varieties 2UCR researchers awarded nearly $1.7M to develop improved cowpea varieties 3UCR researchers awarded nearly $1.7M to develop improved cowpea varieties 4Rutgers scientist's research reveals critical knowledge about the nervous system 2NASA technology helps predict and prevent future pandemic outbreaks 2